Literature DB >> 17719253

Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit.

David L Hwang1, Phillip D K Lee, Pinchas Cohen.   

Abstract

OBJECTIVE: The mouse serves as an important model for insulin-like (IGF)-related research. However, lack of homologous mouse assays has prevented studies of the normal ontology of the murine IGF system. Therefore, we developed and validated immunoaassays for murine IGF-I, IGFBP-3 and ALS and studied levels of these analytes in mice.
METHODS: Using commercially available reagents, we developed and validated specific enzyme-linked immunosorbent assays (ELISAs) for murine IGF-I, IGFBP-3, and ALS. Levels of these analytes were measured in sera from CD-1 mice, male and female, sampled at 1, 2, 4, 8, 20 and 32 weeks of age. In addition, sera from pregnant and postpartum CD-1 mice were also studied.
RESULTS: Validation of specific ELISAs for murine IGF-I, IGFBP-3 and ALS are described; all 3 assays were highly sensitive, precise and accurate. As measured by our homologous ELISA, IGF-I levels (ng/mL, mean+/-SD) in male mice were relatively low at 1 week (53+/-8), rising sharply to peak at 8 weeks of age (636+/-48), and gradually declining thereafter, reaching 395+/-64 at 32 weeks. IGF-I levels in non-pregnant female mice peaked at 4 weeks of age (548+/-77) declined at 8 weeks (417+/-61), then recovered to plateau at 539+/-78 and 535+/-88 at 20 and 32 weeks, respectively. In male mice, trends in IGFBP-3 were similar to the patterns of IGF-I. However, in non-pregnant female mice, the IGFBP-3 levels declined relatively slowly after peaking at 4-weeks of age, unlike IGF-I levels during this period. ALS levels followed the same pattern as IGF-I in both sexes. IGF-I to IGFBP-3 molar ratios (percent) were similar between sexes, rising continuously with age: approximately 30% at 1 week, 80% at 4 weeks, 135% at 32 weeks. IGF-I was reduced in 8 week old mice in mid-pregnancy (354+/-75 vs 417+/-61 in non-pregnant 8 week females), reaching a nadir in late-term (146+/-40), and only partially recovering in the postpartum period (239+/-23). IGFBP-3 was also lower in late-pregnancy (1245+/-100 vs 1925+/-439) and remained depressed postpartum. In contrast to IGF-I and IGFBP-3, ALS increased more than threefold in mid-pregnancy (12180+/-1641 vs 3741+/-910), followed by a 4-fold decrease in late-pregnancy (2964+/-489), recovering postpartum (6104+/-1178).
CONCLUSIONS: We report the first ontological studies of IGF-I, IGFBP-3 and ALS in mice using newly-characterized sensitive, homologous immunoassays. Our results indicate that mice have a generally similar pattern in IGF-related axis components, with low levels early in life, increasing to peak during sexual maturation and declining thereafter. Significant gender differences in non-pregnant levels and dramatic changes during pregnancy were also found. Knowledge of the normal developmental changes in the murine IGF system and accurate tools for investigations of this system are a necessary foundation for research in this field.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719253      PMCID: PMC2276237          DOI: 10.1016/j.ghir.2007.07.007

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  37 in total

Review 1.  Cellular actions of the insulin-like growth factor binding proteins.

Authors:  Sue M Firth; Robert C Baxter
Journal:  Endocr Rev       Date:  2002-12       Impact factor: 19.871

2.  Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice.

Authors:  T Modric; J V Silha; Z Shi; Y Gui; A Suwanichkul; S K Durham; D R Powell; L J Murphy
Journal:  Endocrinology       Date:  2001-05       Impact factor: 4.736

3.  Measurement of the acid-labile subunit of the insulin-like growth factor binding protein complex in human serum: a comparison of four immunoassays.

Authors:  R C Baxter; M Svejkar; M J Khosravi; G L Bennett; K V Hardman; A Senese; J Mistry; P E Walton; V Quarmby
Journal:  J Endocrinol       Date:  2000-05       Impact factor: 4.286

4.  Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site immunoassay for ALS measurement in humans.

Authors:  S Stadler; Z Wu; R A Dressendörfer; K M Morrison; A Khare; P D Lee; C J Strasburger
Journal:  J Immunol Methods       Date:  2001-06-01       Impact factor: 2.303

Review 5.  Insights from insulin-like growth factor binding protein transgenic mice.

Authors:  Josef V Silha; Liam J Murphy
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

6.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation.

Authors:  A Juul; P Dalgaard; W F Blum; P Bang; K Hall; K F Michaelsen; J Müller; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

8.  Effects of lactation on metabolic and reproductive hormones in Lipizzaner mares.

Authors:  B Heidler; N Parvizi; H Sauerwein; R M Bruckmaier; U Heintges; J E Aurich; C Aurich
Journal:  Domest Anim Endocrinol       Date:  2003-07       Impact factor: 2.290

9.  Susceptibility to postnatal growth retardation induced by 5-AZA-2'-deoxycytidine in utero: gender specificity and correlation with reduced insulin-like growth factor 1.

Authors:  Francisco Javier Cisneros; Ralph Wilson; Gregory Travlos; Lucy M Anderson; Stacy Branch
Journal:  Life Sci       Date:  2003-05-09       Impact factor: 5.037

10.  Serum insulin-like growth factor binding protein-3 in the hypophosphatemic mouse: decreased activity and abnormal modulation by dietary phosphate.

Authors:  T Moriwake; T Abribat; P Brazeau; B Ecarot
Journal:  J Bone Miner Res       Date:  1995-11       Impact factor: 6.741

View more
  17 in total

1.  Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation.

Authors:  P M Yamada; H H Mehta; D Hwang; K P Roos; A L Hevener; K W Lee
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

2.  The acid-labile subunit is required for full effects of exogenous growth hormone on growth and carbohydrate metabolism.

Authors:  Iori Ueki; Sarah L Giesy; Kevin J Harvatine; Jin Wook Kim; Yves R Boisclair
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

3.  Chemoprevention of prostate cancer with lycopene in the TRAMP model.

Authors:  Ramdev Konijeti; Susanne Henning; Aune Moro; Ahmed Sheikh; David Elashoff; Ari Shapiro; Melvin Ku; Jonathan W Said; David Heber; Pinchas Cohen; William J Aronson
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

4.  Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents.

Authors:  Yung-Ping Chin; Jyotsna Keni; Junxiang Wan; Hemal Mehta; Francine Anene; Yue Jia; Yan-He Lue; Ronald Swerdloff; Laura J Cobb; Christina Wang; Pinchas Cohen
Journal:  Endocrinology       Date:  2013-07-08       Impact factor: 4.736

5.  Insulin-like growth factor (IGF)-I and IGF-II contribute differentially to the phenotype of pregnancy associated plasma protein-A knock-out mice.

Authors:  Emily J Mason; Jacquelyn A Grell; Junxiang Wan; Pinchas Cohen; Cheryl A Conover
Journal:  Growth Horm IGF Res       Date:  2011-07-28       Impact factor: 2.372

6.  Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration.

Authors:  Merry Christie; Raul M Torres; Ross M Kedl; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

7.  The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes While Enhancing Chemotherapy-Induced Suppression of Cancer Metastases in Male Mice.

Authors:  YanHe Lue; Ronald Swerdloff; Junxiang Wan; Jialin Xiao; Samuel French; Vince Atienza; Victor Canela; Kevin W Bruhn; Brian Stone; Yue Jia; Pinchas Cohen; Christina Wang
Journal:  Endocrinology       Date:  2015-09-18       Impact factor: 4.736

8.  Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression.

Authors:  Makoto Anzo; Laura J Cobb; David L Hwang; Hemal Mehta; Jonathan W Said; Shoshana Yakar; Derek LeRoith; Pinchas Cohen
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

Authors:  James P Dean; Cynthia C Sprenger; Junxiang Wan; Kathleen Haugk; William J Ellis; Daniel W Lin; John M Corman; Bruce L Dalkin; Elahe Mostaghel; Peter S Nelson; Pinchas Cohen; Bruce Montgomery; Stephen R Plymate
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

10.  IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.

Authors:  Gordon Moody; Pedro J Beltran; Petia Mitchell; Elaina Cajulis; Young-Ah Chung; David Hwang; Richard Kendall; Robert Radinsky; Pinchas Cohen; Frank J Calzone
Journal:  J Endocrinol       Date:  2014-03-17       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.